9 Samh 2023 · Note: Metabolic sub-study PIS will only be provided to sites participating in the sub-study.

STAMPEDE is a large clinical trial that aims to assess new treatment approaches for people affected by high-risk prostate cancer. The trial has been open since 2005 and has tested many different ways of …

27 Iúil 2017 · STAMPEDE is a multigroup, multistage platform trial protocol investigating the efficacy of additional therapy at the time of inception of primary ADT in men with newly diagnosed, locally...

18 Aib 2023 · STAMPEDE (also known as MRC PR08) is a multi-arm multi-stage (MAMS) randomised controlled trial recruiting in the UK and Switzerland. It aims to evaluate multiple therapeutic strategies …

1 Noll 2018 · We aimed to compare standard of care for metastatic prostate cancer, with and without radiotherapy. We did a randomised controlled phase 3 trial at 117 hospitals in Switzerland and the UK. …

Background: Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic …

STAMPEDE is a multi-centre, randomised controlled trial for patients with locally advanced or metastatic prostate cancer who are about to commence androgen suppression (AS) therapy.

What dose do you prescribe when treating the prostate in patients with low metastatic burden and what are your dose constraints? The STAMPEDE trial recently published in Lancet used 55 Gy in 20 …

The STAMPEDE trial has now completed recruitment. The final day of patient randomisation was completed on 31st March 2023. The STAMPEDE Trial is supported by Cancer Research UK [Grant # …

12 DFómh 2023 · Prof Attard briefly reviewed the STAMPEDE platform patient population by explaining that those enrolled in the trial are stratified into 2 groups: the M1 group (mHSPC) based on imaging, …